Journal of Thrombosis and Thrombolysis

, Volume 36, Issue 1, pp 7–13 | Cite as

Identifying, monitoring and reducing preventable major bleeds in the hospital setting

  • Deborah Caraballo
  • Alex C. Spyropoulos
  • Charles E. Mahan


Recent literature describes methods to reduce “preventable” hospital-acquired venous thromboembolism; however, there is a paucity of data on “preventable” bleeding. While risk assessment models exist for both thrombosis and bleeding, these concepts should be differentiated from whether the event was preventable or non-preventable. Here we describe a protocol to identify, monitor, and evaluate anticoagulation-related preventable hospital-acquired major bleeds (PHAMB). This single-center, prospective observational study with retrospective chart review was conducted in 2009 and 2010 to identify anticoagulation-related major bleeding. Eligible anticoagulation-related hospital-acquired major bleeds (HAMB) were further classified as “preventable” or “non-preventable”. A total of 229 major bleed episodes were identified of which 188 were excluded due to being community-acquired or non-anticoagulation related major bleeds. Over the 2 year period, five of the 41 HAMB were classified as preventable providing a total incidence of 13 % PHAMB. Three and two of the PHAMB were due to inappropriate dosing and administration of an anticoagulant when contraindications existed, respectively. PHAMB rates decreased from 0.06 in 2009 to 0.04 per 1000 patient days in 2010 (p = 0.62) although this difference was not statistically significant. Raw incidence utilizing Joint Commission methodology demonstrated a 16.7 % rate in 2009 and an 8.7 % rate in 2010. In hospitalized patients, intervention programs may minimize the incidence of anticoagulation-related PHAMB and may maintain similar rates of preventable bleeding over time. Similar programs should be explored prospectively on a larger scale to reduce harm from anticoagulants in the hospital setting.


Preventable Major bleeds Hospital-acquired Anticoagulation-related 


  1. 1.
    Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):257S–298S. doi:133/6_suppl/257S10.1378/chest.08-0674 PubMedCrossRefGoogle Scholar
  2. 2.
    Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, Manoukian SV, Nikolsky E, Lansky AJ, Kirtane A, White HD, Colombo A, Ware JH, Moses JW, Ohman EM (2009) Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 30(12):1457–1466. doi:ehp11010.1093/eurheartj/ehp110 PubMedCrossRefGoogle Scholar
  3. 3.
    Ewen EF, Zhao L, Kolm P, Jurkovitz C, Fidan D, White HD, Gallo R, Weintraub WS (2009) Determining the in-hospital cost of bleeding in patients undergoing percutaneous coronary intervention. J Interv Cardiol 22(3):266–273. doi:JOIC43110.1111/j.1540-8183.2009.00431.x PubMedCrossRefGoogle Scholar
  4. 4.
    Maynard GA, Morris TA, Jenkins IH, Stone S, Lee J, Renvall M, Fink E, Schoenhaus R (2010) Optimizing prevention of hospital-acquired venous thromboembolism (VTE): prospective validation of a VTE risk assessment model. J Hosp Med 5(1):10–18. doi:10.1002/jhm.562 PubMedGoogle Scholar
  5. 5.
    Mahan CE, Hussein MA, Amin AN, Spyropoulos AC (2012) Venous thromboembolism pharmacy intervention management program with an active, multifaceted approach reduces preventable venous thromboembolism and increases appropriate prophylaxis. Clin Appl Thromb Hemost 18(1):45–58. doi:107602961140518610.1177/1076029611405186 PubMedCrossRefGoogle Scholar
  6. 6.
  7. 7.
    TJC’s National Patient Safety Goals. 8 Aug 2012
  8. 8.
    Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W (2010) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8(1):202–204. doi:JTH367810.1111/j.1538-7836.2009.03678.x PubMedCrossRefGoogle Scholar
  9. 9.
    Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694. doi:JTH120410.1111/j.1538-7836.2005.01204.x PubMedCrossRefGoogle Scholar
  10. 10.
    Bullano MF, Willey V, Hauch O, Wygant G, Spyropoulos AC, Hoffman L (2005) Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 11(8):663–673PubMedGoogle Scholar
  11. 11.
    Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R et al (1995) Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 274(1):29–34PubMedCrossRefGoogle Scholar
  12. 12.
  13. 13.
    National Voluntary Consensus Standards for Prevention and Care of Venous Thromboembolism: additional performance measures. Accessed 10 Feb 2012
  14. 14.
  15. 15.
    Mahan CE, Spyropoulos AC (2010) Venous thromboembolism prevention: a systematic review of methods to improve prophylaxis and decrease events in the hospitalized patient. Hosp Pract (Minneap) 38(1):97–108CrossRefGoogle Scholar
  16. 16.
    Chopard P, Dorffler-Melly J, Hess U, Wuillemin WA, Hayoz D, Gallino A, Bachli EB, Canova CR, Isenegger J, Rubino R, Bounameaux H (2005) Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement. J Intern Med 257(4):352–357. doi:JIM145510.1111/j.1365-2796.2005.01455.x PubMedCrossRefGoogle Scholar
  17. 17.
    Khalili H, Dashti-Khavidaki S, Talasaz AH, Mahmoudi L, Eslami K, Tabeefar H (2010) Is deep vein thrombosis prophylaxis appropriate in the medical wards? A clinical pharmacists’ intervention study. Pharm World Sci 32(5):594–600. doi:10.1007/s11096-010-9412-y PubMedCrossRefGoogle Scholar
  18. 18.
    Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK, Merli GJ, Monreal M, Nakamura M, Pavanello R, Pini M, Piovella F, Spencer FA, Spyropoulos AC, Turpie AG, Zotz RB, Fitzgerald G, Anderson FA (2010) Factors at admission associated with bleeding risk in medical patients: findings from IMPROVE. Chest. doi:chest.09-308110.1378/chest.09-3081 PubMedGoogle Scholar
  19. 19.
    Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY (2010) A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest. doi:chest.10-013410.1378/chest.10-0134 Google Scholar
  20. 20.
    Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):160S–198S. doi:133/6_suppl/160S10.1378/chest.08-0670 PubMedCrossRefGoogle Scholar
  21. 21.
    Fox KA, Antman EM, Montalescot G, Agewall S, SomaRaju B, Verheugt FW, Lopez-Sendon J, Hod H, Murphy SA, Braunwald E (2007) The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 49(23):2249–2255. doi:S0735-1097(07)01072-80.1016/j.jacc.2006.12.049 PubMedCrossRefGoogle Scholar
  22. 22.
    White HD, Braunwald E, Murphy SA, Jacob AJ, Gotcheva N, Polonetsky L, Antman EM (2007) Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. Eur Heart J 28(9):1066–1071. doi:ehm08110.1093/eurheartj/ehm081 PubMedCrossRefGoogle Scholar
  23. 23.
    Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355(21):2203–2216. doi:355/21/220310.1056/NEJMoa062437 PubMedCrossRefGoogle Scholar
  24. 24.
    Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, Khattab AA, Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, Dirschinger J, Richardt G, Berger PB, Schomig A (2008) Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 359(7):688–696. doi:359/7/68810.1056/NEJMoa0802944 PubMedCrossRefGoogle Scholar
  25. 25.
    Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289(7):853–863. doi:joc22311 PubMedCrossRefGoogle Scholar
  26. 26.
    Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, Decousus H (2000) Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 83(1):14–19. doi:00010014 PubMedGoogle Scholar
  27. 27.
    Linkins LA, Choi PT, Douketis JD (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 139(11):893–900. doi:139/11/893 PubMedCrossRefGoogle Scholar
  28. 28.
    Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD, Mehta S, Tannenbaum MA, Niederman AL, Bachinsky WB, Tift-Mann J 3rd, Parker HG, Kereiakes DJ, Harrington RA, Feit F, Maierson ES, Chew DP, Topol EJ (2004) Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the randomized evaluation of PCI linking angiomax to reduced clinical events [REPLACE]-1 trial). Am J Cardiol 93(9):1092–1096. doi:10.1016/j.amjcard.2004.01.033S0002914904001237 PubMedCrossRefGoogle Scholar
  29. 29.
    Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML (1988) Thrombolysis in myocardial infarction (TIMI) trial–phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11(1):1–11. doi:0735-1097(88)90158-1 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Deborah Caraballo
    • 1
  • Alex C. Spyropoulos
    • 2
  • Charles E. Mahan
    • 1
  1. 1.New Mexico Heart InstituteUniversity of New MexicoAlbuquerqueUSA
  2. 2.James P Wilmot Medical CenterUniversity of RochesterRochesterUSA

Personalised recommendations